May 31, 2018 7:35am EDT Intensity Therapeutics, Inc. Announces Presentation on INT230-6 Clinical Study at the 2018 ASCO Conference
Feb 27, 2018 7:35am EST Intensity Therapeutics, Inc. Reports Positive Safety Data from Ongoing IT-01 Phase 1/2 Trial
May 30, 2017 7:35am EDT Intensity Therapeutics, Inc. Successfully Administers INT230-6 to First Patient in a Phase 1/2 Trial
Apr 04, 2017 7:35am EDT Intensity Therapeutics Reports That INT230-6 Induces Protective T-Cell Immunity in Preclinical Models
Jun 28, 2016 7:35am EDT Intensity Therapeutics, Inc. Raises $10 Million to Fund Clinical Supplies Manufacturing and Phase I/II Trials of INT230-6
Jun 02, 2016 7:35am EDT Intensity Therapeutics Issued First US Patent for Immune-based Cancer Therapeutic Agents
Apr 19, 2016 7:35am EDT Intensity Therapeutics Reports that INT230-6’s Anti-cancer Mechanism is a Combination of Cell Death with Immune System Activation
